FEATURED ARTICLES

• Challenges That Derail Bladder Cancer Trials And How To Anticipate Them Earlier

  From the rapid evolution of standard-of-care benchmarks to the logistical strain of procedure-heavy urology workflows, the path to a successful endpoint is filled with operational friction.

• Early Phase Oncology Site Network: Benefits Of A Personal Touch

  Choose a site network built on partnership — not volume — to drive smoother early-phase oncology trials and deliver better outcomes for sponsors, sites, and patients.

• The Growing Complexity Of Conducting Oncology Trials

  As diversity plans and multi-regional considerations become core to trial design, early-phase oncology programs must navigate a landscape that offers unprecedented opportunity.

• Precision Medicine: Targeted Cancer Therapies

  Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

• Specialized Site Network For Early-Phase Oncology Success

  Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

• Working With A Specialty Oncology CRO Versus A Large Generalist CRO

  Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

• Key Takeaways From ADCs In Oncology Trials Webinar

  By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

• The Evolving Landscape Of Oncology Drug Development

  Explore the novel drug modalities poised to revolutionize oncology and improve patient outcomes.

• The Resurgence Of Antibody-Drug Conjugates

  As advancements in ADC technology and clinical trial methodologies progress, Antibody-Drug Conjugates (ADCs) are poised to become pivotal in precision oncology.

• Navigating Project Optimus And The Rapidly Changing Oncology Development Landscape

  Project Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.